Company Seeks Shareholder Approval to Increase Authorized Common Stock by 1,425 Million Shares to Fund Operations Amid Going Concern Warning

summarizeSummary

BioRestorative Therapies, Inc. is seeking shareholder approval to increase its authorized common stock from 75 million to 1.5 billion shares, a critical step to raise capital and address its going concern warning and Nasdaq delisting notice.

check_boxKey Events

• Massive Increase in Authorized Shares Proposed

  The company proposes to amend its Articles of Incorporation to increase authorized common stock from 75,000,000 to 1,500,000,000 shares, a 1900% increase in authorization.

• Enables Significant Future Capital Raises

  The primary purpose of the increase is to provide flexibility to issue shares for general corporate purposes, including raising additional capital for clinical trials (BRTX-100), pre-clinical R&D, and working capital.

• Direct Response to Going Concern and Delisting

  This proposal follows the company's 10-K filing on March 26, 2026, which disclosed 'substantial doubt about its ability to continue as a going concern' and a Nasdaq delisting notice for failing to meet the minimum bid price requirement.

• Potential for Extreme Dilution

  With 25,478,170 shares currently outstanding, the proposed authorization of 1.5 billion shares represents a potential for over 5700% dilution if all newly authorized shares were issued.

auto_awesomeAnalysis

This preliminary proxy statement reveals BioRestorative Therapies, Inc. is seeking shareholder approval to dramatically increase its authorized common stock from 75 million to 1.5 billion shares. This massive increase, representing a potential dilution of over 5700% relative to current outstanding shares, is a critical step for the company to raise capital. The filing explicitly states the intent to issue shares for general corporate purposes, including funding clinical trials for BRTX-100 and other R&D, and for working capital. This move directly addresses the 'substantial doubt about its ability to continue as a going concern' disclosed in the recent 10-K filing on March 26, 2026, and the Nasdaq delisting notice received on the same date. While highly dilutive, this authorization is essential for the company's survival and to capitalize on the recent positive Phase 2 data for BRTX-100 announced on March 30, 2026. Investors should anticipate significant future dilution as the company executes capital raises enabled by this authorization.